ShareThis Page
Pitt’s LifeX biotechnology center starts with $2M grant from Hillman Foundation |

Pitt’s LifeX biotechnology center starts with $2M grant from Hillman Foundation

| Wednesday, April 18, 2018 12:33 p.m.
Samples of mini organs are magnified with microscope at the Hubrecht Institute in Utrecht, Netherlands, on Monday, May 29, 2017.

University of Pittsburgh’s biotechnology center will tackle some of medicine’s biggest challenges for its initial focus.

LifeX’s first batch of companies are working on therapies, drugs and medical innovations to fight cancer and on treatments to address Alzheimer’s disease, multidrug resistant bacteria, obesity, diabetes and rare genetic diseases.

The biotech commercialization center launched by Pitt in December opened its first headquarters in the Strip District this week and announced a $2 million grant from the Henry L. Hillman Foundation to help it get off the ground. More information about its first cohort of companies is available on its website .

“Pittsburgh’s life sciences pioneers brought the world the polio vaccine, liver transplantation and innumerable other innovations that have transformed the lives of so many across the globe,” Dietrich Stephan, CEO and founder of LifeX, said in a statement. “The LifeX team is proud to have the Hillman Foundation’s support as we continue this longstanding legacy of facilitating cures to the most devastating and prevalent causes of suffering and death.”

LifeX’s headquarters will be a mix of office and lab space. The center hopes to pair entrepreneurs with health experts experienced in formulating new pharmaceuticals, designing new medical devices and other skills.

LifeX is raising $25 million to invest as early-stage capital in the companies working in its lab. LifeX also is raising money for a larger fund that will invest in other companies and in developing an investment portfolio of startup pharmaceutical companies.

TribLIVE commenting policy

You are solely responsible for your comments and by using you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.